Primary Sj€ ogren's syndrome (pSS) is a chronic autoimmune disease characterized by exocrine gland dysfunction, mainly causing sicca symptoms. B cells have a prominent role in SS, and the T follicular helper (T FH ) cells provide B cells with survival and specialization signals in germinal centres. Here, we investigate peripheral T FH cells in pSS. Sixteen pSS patients and healthy controls were enrolled in the study, with 13 women and 3 men in each group. Whole blood was collected and separated into PBMC and plasma, followed by cryopreservation. Plasma samples were analysed for Ro52, Ro60 and La48 autoantibodies by indirect ELISA. For flow cytometric analysis, we defined 4 subsets of TFH-like cells within the CD3 
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| INTRODUCTION
Sj€ ogren's syndrome (SS) is a chronic rheumatic autoimmune disease characterized by impaired exocrine glandular function. This is due to infiltration by mononuclear cells, primarily affecting salivary and lacrimal glands, causing dryness of eyes (keratoconjunctivitis sicca) and mouth (xerostomia). 1 Other common symptoms of SS patients are general signs of inflammation, such as muscle and joint aches, mild fever and fatigue. 2, 3 SS can be organ-specific, where the disease is limited to distinct organs (like salivary and lacrimal glands), or systemic, involving extra-glandular manifestations (commonly skin, lungs and peripheral nerves). Auto-antibodies against the Ro/SSA and La/SSB antigens are commonly found in SS patients and are an important diagnostic indicator of the disease. The T follicular helper cells (T FH ) make up a subpopulation within the T helper (T H ) cells that reside in the B cell area of the secondary lymphoid organs. T FH cells are important in the germinal centre reaction where they assist B cells in isotype switching, somatic hypermutation and affinity maturation. 4 The T FH cells express a combination of molecules that are crucial for their development and function. This includes high levels of the chemokine receptor CXCR5, inducible T cell costimulator (ICOS), Programmed cell death protein-1 (PD-1), CD40 ligand (CD40L), 0X40, SLAM-associated protein (SAP), the transcription factors Bcl-6 and c-Maf and production of the cytokine IL-21. 4 Expression of the B cell zone homing chemokine receptor CXCR5 and down-regulation of the T cell zone homing chemokine receptor CCR7 enables T FH cells to reside in the B cell zone where they execute their function. 5 The interaction between ICOS and its ligand B7-related protein-1 (B7RP-1), expressed on antigen presenting cells (APCs), is essential for optimal B cell differentiation and heavy chain isotype switching. 6, 7 Furthermore, Crotty et al. 8 suggested that the formation of plasma cells and T effector memory cells are dependent on SAP molecule which is expressed on the T FH cells. Interestingly, mutations in this gene have been linked to hypogammaglobulinemia. 9 The transcription factor B cell lymphoma 6 (Bcl-6) is the main T FH cell regulator and is largely confined to the germinal centre T and B cells. 4 In activated T cells, the c-Maf induces production of IL-21, which is a cytokine crucial for B cell proliferation and differentiation. 10 CD40L is critical for germinal centre B cell survival, 4 whilst PD-1 inhibits T cell signalling in germinal centres and thereby prevents excessive antibody responses. 11 Traditionally, the T FH cells were mainly defined by their anatomical location, but recent studies have revealed the existence of peripheral analogues. A key difference between the stationary and circulating T FH cells is that the latter lack expression of Bcl-6.
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The objective of this study was to investigate T FH -like cells and study their possible pathological relationship to B cell subsets, ie memory B cells, plasmablasts and plasma cells, in peripheral blood of pSS patients. Additionally, the pathological relationship was related to clinical findings in the pSS patients and Ro/La autoantibodies.
| MATERIAL AND METHODS

| Patients and controls
Sixteen primary Sj€ ogren's syndrome patients and 16 controls where enrolled in this study, including 13 women and 3 men in both groups. The patients were recruited from the Rheumatology Clinic at Haukeland University Hospital (HUH), Bergen, Norway. All patients fulfilled the American European Consensus Group (AECG) criteria. 13 for Primary Sj€ ogren's syndrome (Table 1) . Demographics and clinical data were extracted from medical records and provided by the Department of Rheumatology at HUH. The patients' mean age was 60 years (range: 29-85 years). Control volunteers above 40 years of age were recruited at the Blood Bank at HUH, with a mean age of 52 years (range: 40-65 years). All patients and controls received written and oral information, and participating patients provided a signed consent. The study has been approved by the regional ethical committee (REK.no: 3.2006.3085).
| Sample collection, handling and storage
Samples were collected in the period September to late November 2015. Peripheral blood was drawn in heparin tubes and processed within 1 hour of sampling. The whole blood was diluted 1:2 with PBS, and separated by density gradient centrifugation (800 g, 20 minutes, 22°C, brake off) using Lymphoprep (LYS3773; Axis-Shield, UK) into plasma and mononuclear cell (PBMC) fractions. The plasma was aliquoted and stored at À70°C. The PBMCs were resuspended in freezing medium (FM; 20% DMSO, D5879-500ML; Sigma-Aldrich, USA, 80% FBS; PAA A15-151; PAA laboratories, USA) and frozen in a freezing container, giving a controlled cooling rate of À1°C/min down to À70°C, minimizing the risk of crystal formation. The cells were stored in a liquid nitrogen container.
| Plasma-ELISA
The plasma levels of autoantibodies against Ro52, Ro60 and La48 was performed as described in a previous publication. 14 Briefly; Microlon medium binding plates were coated with 0.1 lg/100 mL/well recombinant autoantigen. For all our studies, we have used affinity purified full length human recombinant Ro52, Ro60 and La48 as described in Garberg et al. 14 Fetal Calf Serum (FCS) was used to block unbound areas, and extensive washing was performed between each step (PBS with 0.5% Tween). The plasma was added to the wells in duplicate at 1:1000 dilution. Detection antibody was goat-anti-human-IgG POX conjugated (A0293; SigmaAldrich) and using the OPD substrate. The plates were read at OD 492 nm with a Biotek Synergy H1 microplate reader. The cut-off value for a positive serology was set to the mean optical density (OD) of the control subjects plus 2 standard deviations (SD). The cut-off values were calculated to 0.120, 0.230 and 0.150 for Ro52, Ro60 and La48, respectively ( Figure S1 ).
| Cells-flow cytometry
Cell growth conditions: LM: RPMI 1640, BE 12-702F/U1, Lonza, Belgium, +10% FBS +1% Penicillin, Streptomycin and Amphotericin B, 17-745E, Lonza. AM: LM + 1 lg/ mL Mouse anti-human CD28, 1 lg/mL Mouse anti-human CD49d. Ro/La: AM + Ro52/Ro60/La48 cocktail 1 lg/mL of each autoantigen. PHA: AM + 1 lg/mL PHA-L, L4144, Sigma-Aldrich. The frozen PBMC samples were rapidly defrosted in prewarmed (37°C) lymphocyte medium (LM) and washed multiple times in LM. Finally, the cells were suspended in 1 mL of LM and counted using Casyton (05651808; Roche Innovatis, Germany), and the cell suspension was adjusted to 1 
| Statistical analysis
Graphs and Statistics were performed using Prism for Mac OS X v.5.0f (GraphPad Software). The significance of the results was determined using Welch 0 s unequal variances t test when comparing pSS patients with controls. Non-parametric-paired t test was used when comparing the effect of various stimulation media on subsets within the same subject group. P-values <.05 were considered significant.
| RESULTS
In this study, samples from 16 age and sex matched pSS patients and controls were analysed for Ro/SSA and La/ SSB autoantibodies and flow cytometry was used to quantify T FH -like cells and B cell subsets (ie memory cells, plasmablasts and plasma cells). 
| Serological detection of autoantibodies against Ro52, Ro60 and La48
Indirect ELISA was conducted to determine the levels of plasma autoantibodies against Ro52, Ro60 and La48. All the controls had anti-Ro and La serology deemed negative. There were significant differences between pSS patients and controls for Ro52 (P = .0003), Ro60 (P = .0045) and La48 (P = .0234; Figure S1 ). The results from in-house ELISA were compared with the data from the routine diagnostic lab at the Rheumatology Clinic (Table S2) . Only 4 pSS patients showed inconsistent serology results between the in-house analysis and the test performed at the clinical routine laboratory.
| Flow cytometry
Plasma and mononuclear cells from pSS patients and control subjects were either left unstimulated or exposed for 16 hours in one of the following stimulation media; activation media (AM), recombinant Ro/La cocktail (1 lg/mL) in AM or PHA (1 lg/mL) in AM as a positive control. The cells were then fixed and stained with antibody panels, identifying T FH -like cells and B cell subsets followed by flow cytometric analysis. Figure 1B ).
| Levels of T FH -like cells in pSS
Four subsets of T FH -like cells were identified within the Figure 2A ) were significantly lower in the patients compared to the controls when the cells were AM cultivated (P = .0223) and RoLa-stimulated (P = .0135). The same tendency was seen with the unstimulated (mean AE SD; pSS = 5.0 AE 2.8%, C = 5.5 AE 3.3%), and PHA stimulated (pSS = 1.5 AE 0.7%, C = 1.7 AE 0.8%) samples but the differences were not significant. The fraction of ICOS À PD-1 À population decreased with stimulation with RoLa (P = .0087) and PHA (P = .0002) for patients. A significantly higher level of ICOS
ure 2B) was observed in pSS patients (0.4 AE 0.2%) compared to controls (0.3 AE 0.1%; P = .0397), in unstimulated samples. The proportion increased significantly from the AM-stimulated to the RoLa-stimulated samples for both groups (C P = .0009, pSS P = .0214). The number of ICOS À PD-1 + cells decreased slightly with stimulation ( Figure 2C) , and there was no significant difference between the pSS patients and controls. The proportion of ICOS+PD-1+ ("T FH ")-cells was significantly higher within the patient group compared to the controls, in the unstimulated (P = .0136), AM-stimulated (P = .0049) and RoLastimulated (P = .0116) samples ( Figure 2D ). In unstimulated samples, the level of "T FH "-cells was 0.14 AE 0.12% (mean AE SD) for the pSS patients, and 0.05 AE 0.04% for the control subjects, indicating a 2.8-fold difference. The proportion was significantly higher in the RoLa-stimulated samples compared to the AM-stimulated samples for both groups (C; P = .0026, pSS; P = .0084).
| Levels of B cell subsets in pSS
The total level of B cells (CD19 + ) when cultured in activation medium (AM) with and without RoLa or PHA, did not increase significantly in either patients or controls (Figure 3) .
Four subsets of B cells were of particular interest, namely CD38
À memory B cells, CD38 + memory B cells, plasmablasts and plasma cells using the following markers to distinguish the cell subsets; CD19, CD20, CD27, CD38 and CD138 ( Figure 4 ). Controls had significant higher CD38 À memory cells between patients and controls in all 4 groups of stimuli, where controls had consistently higher levels (US P = .0003, AM P = .0013, RoLa P = .0010, PHA P = .0157). The level of CD38 À memory cells decreased significantly in PHA-treated cells compared to the unstimulated groups (pSS P = .0047, C P = .0317), but not for the other treatment groups. The fraction of CD38 + memory B cells was significantly lower within the patient group compared to the controls under all the tested conditions (Unstim P = .0065, AM P = .0443, RoLa P = .0163, PHA P = .0112). In unstimulated cell samples, the level of CD38 + memory cells was 11.8 AE 4.9% for the pSS patients and 16.9 AE 5.0% for the controls, 1.4-fold higher in controls. An increased level of plasmablasts was observed in unstimulated samples of pSS patients (1.9 AE 1.8%) compared to controls (0.9 AE 0.6%; P = .0490). This difference was also observed between patients and controls in AM (P = .0447) and RoLa (P = .0414). The level of plasmablasts dropped when cultivating with AM, RoLa and PHA in both the patient (P = .0026, P = .0025, P = .0023) and control groups (P = .0001, P = .0001, P = .0001) compared to unstimulated cells. No difference was observed between patients and controls in plasma cell numbers, but the levels dropped significantly in the cultivated cells groups; AM (P = .0081 and P = .0036), RoLa (P = .0165 and P = .0069) and PHA (P = .0362 and P = .0085) for both patients and controls, respectively.
| Levels of T FH -like cells in pSS patients grouped according to Ro/La serology
The pSS patients were stratified into groups according to Ro/La serology results from indirect ELISA (Table S3 and Figure 1 ); serum negative (À, n = 3), single positive (+, n = 2), double positive (++, n = 4) and triple positive (+++, n = 7) subjects against Ro52, Ro60 and La48. , with a significant difference between serum negatives and triple positives under all conditions. Although when stratifying patients with respect to Ro/La serology, we were not able to observe any changes in CD38 + memory cell levels.
The levels of both plasma cells and plasmablasts were more prominent with stronger Ro/La serology ( Figure 7) . The plasmablast levels were 0.4 AE 0.4% in serum negative patients and 2.6 AE 1.6% in triple positive patients (P = .0117). For plasma cells the levels were 0.005 AE 0.004% and 0.03 AE 0.02%, respectively (P = .0094).
| Comparison of pSS patients according to the level of "T FH "-cells
The pSS patients were divided into 2 groups reflecting their level of ICOS + PD-1 + ("T FH ") cells. Patients expressing an elevated level of "T FH " cells were defined as "T FH "-hi (n = 7), while those being under average were defined as "T FH "-lo (n = 9; Figure 8 ). Figure 8 shows the proportion of B cell subsets in unstimulated samples sorted after "T FH "-profile, and linear correlation plots regarding levels of plasmablasts and plasma cells in relation to "T FH " level. No associations were established between B cell subsets and "T FH " cells in control subjects (not shown). The number of "T FH " cells in pSS patients correlated with the level of plasmablasts (P = .0251) and plasma cells (P = .0029; Figure 8 , panels C and D). Considering "T FH "-hi vs "T FH "-lo individuals, the same association was found (PB P = .0248, PC P = .007). The levels of plasmablasts were 3.2 AE 2.1% and 0.9 AE 0.6%, respectively, indicating a 3.6-fold difference. As concerns the plasma cells, the levels were 0.05 AE 0.03% and 0.01 AE 0.01%, suggesting a 5-fold difference.
No significant differences were found between the 2 groups looking at the memory B cells (MC CD38 À P = .1428, MC CD38 + P = .3291). However, the "T FH "-hi groups showed a significant higher level of CD38 + MCs compared to CD38 À MCs (P = .0326). This association was not found with the "T FH "-lo group (P = .7344).
| Comparison of pSS patients sorted by clinical data
The pSS patients were stratified according to clinical features, ie focus score (FS < 2 n = 7, FS ≥ 2 n = 3), rheumatoid factor (RF ≤ 11 n = 9, RF > 11 n = 4), autoantibodies (ANA/SSAÀ n = 4, ANA/SSA+ n = 12) and disease activity score (ESSPRI ≤ 5 n = 4, ESSPRI > 5 n = 12; Table 1 ). Figure 9 shows the proportions of investigated B cell subsets and T FH -like cells in unstimulated samples sorted accordingly. Regarding T FH -like cells, the levels were similar comparing the subgroups of RF and ESSPRI (ie RF ≤ 11 vs RF > 11 and ESSPRI ≤ 5 vs ESSPRI > 5), whilst there was a general trend of higher levels in ANA/SSA+ patients compared to ANA/SSAÀ patients. However, the difference was only significant for the ICOS + PD-1
Regarding the memory B cells, the same trend was observed when sorting by ANA/SSA and ESSPRI-the groups with clinical features indicating increased disease activity (ie ANA/SSA+ and ESSPRI > 5) had decreased levels of CD38 À MCs and raised levels of CD38 + MCs.
Even so, the difference was only significant for CD38
À MCs comparing the subdivisions of ANA/SSA (P = .0030).
In terms of rheumatoid factor, the patients with RF > 11 showed tendencies of lowered levels of both CD38 À and CD38 + MCs, although not significant.
The pSS patients with indications of highest disease activity (ie RF > 11, ANA/SSA+, ESSPRI > 5) had higher levels of CD38
+ MCs compared to CD38 À MCs, although not significant for the RF subdivision (RF > 11 P = .1250, ANA/SSA+ P = .0005, ESSPRI > 5 P = .0269). For those with indications of lowest disease activity, this was also shown for the RF ≤ 11 and the opposite for the ANA/ SSAÀ group, although not significant (RF ≤ 11 P = .4258, ANA/SSAÀ P = .1250). The ESSPRI ≤ 5 group had similar levels of CD38 À MCs and CD38 + MCs.
Considering plasmablasts and plasma cells, the subgroups of RF, ANA/SSA and ESSPRI showed the same pattern-the levels were higher in patients with elevated levels of autoantibodies/highest ESSPRI score. However, the difference was only significant when sorted according to ANA/SSA (PB P = .0337, PC P = .0343).
| DISCUSSION
Sj€ ogren's syndrome (SS) is a chronic autoimmune disease with involvement of a strong B cell component in the etiopathogenesis of the disease. The T follicular helper cells are vital in the formation and maintenance of germinal centres, where they also function as B cell coordinators, selecting promising clones to survive, expand and differentiate. 4 The T FH cells may play an important role when auto-reactive plasma cells are formed in the target tissue of SS patients. In addition, T FH cells may be essential in the lymphoid cell infiltration and formation of germinal centrelike structures in exocrine glands. Sixteen pSS patients and 16 healthy controls were enrolled in the study. Indirect ELISA has been used to analyse plasma samples for Ro52, Ro60 and La48 autoantibodies, whilst PBMCs were used for quantification of distinct subsets by flow cytometry. The focus of this study was to investigate the relation between the T FH -like cells, B cell activity and clinical factors in patients with pSS.
| Ro52, Ro60 and La48 autoantibody serology
Indirect ELISA was used to examine the presence of Ro52, Ro60 and La48 autoantibodies in plasma samples of healthy controls and pSS patients (Table S3 and Figure S1 ). We found that 75%, 69% and 50% of the patients expressed Ro52, Ro60 (anti-SSA = 81%) and La48, respectively. The results from in-house ELISA were compared with data from the routine diagnostic lab (Table 1 and Table S2 ). Only 4 patients showed minor inconsistent serology in the 2 assays, and 2 of them (ie patient no. 8 and 11) had values that were close to cut-off. The clinical data from the Rheumatology Department was obtained when establishing the pSS diagnosis which was not the same time point as the sampling in this study, and thus the serum titres may have drifted between the sample collection time points. 
cells in pSS
The control subjects had a slightly increased number of T helper cells (CD3 + CD4 + ), but when in addition gating for CXCR5, the difference between the groups was reduced (Figure 1 ). This indicates that there are less CD4 + T cells in the controls expressing CXRC5 + suggesting less migration against the lymph nodes. We detected a significantly higher level of ICOS + PD-1 + ("T FH ") cells in pSS patients
compared to controls under all tested culture conditions (Figure 2 ), although the ICOS 
| Lowered number of memory B cells in pSS
We found significantly lower proportions of CD38 À and CD38 + memory B cells in pSS patients compared to controls under all tested conditions (Figure 3 ), which is consistent with previous reports. 19, 20 
| A Positive correlation between pSS and the levels of plasmablasts and plasma cells
We observed a significantly higher proportion of plasmablasts in pSS patients compared to controls, showing a positive correlation between plasmablasts and pSS (Figure 3 
| Ro/La-specific memory B cells in pSS
We detected significantly lower proportions of memory B cells (both CD38 À and CD38 + MCs) in patient samples being RoLa-stimulated compared to AM-stimulated (Figure 3) . In controls, this association was only made for CD38 À MCs. Since all controls were serum negative for Ro/La, this could imply a non-specific response to the Ro/ La autoantigens. However, the magnitude of the response differed between the pSS patients and the controls (Figure 3) , with the highest decrease observed in patients. The difference was only significant for the CD38 À MCs, but the same trend was observed with the CD38 + MCs. As discussed earlier, a decreased level of memory B cells may be a sign of activation and differentiation. 
| Level of "T FH " cells correlates with levels of plasmablasts and plasma cells in pSS
We defined 2 groups of pSS patients based on their levels of "T FH " cells ( Figure 8 ). Those categorized as "T FH -hi," expressed significantly higher levels of plasmablasts and plasma cells compared to subjects in the "T FH -lo" group. The level of "T FH " cells was also shown to correlate positively with the levels of plasmablasts and plasma cells. In addition, the "T FH -hi" group had a significantly higher level of CD38 + memory B cells compared to CD38 À memory B cells. In the "T FH -lo" group, these levels were similar. The observed skewing towards CD38 + MCs in "T FHhi" patients is therefore suggestive of a connection between "T FH " cells and activated memory B cells. Overall, we believe these findings substantiate the role of the "T FH cells" in B cell activity.
| Association between investigated cell subsets and disease activity in pSS
We divided the pSS patients into groups according to clinical features (ie FS, RF, ANA/SSA and ESSPRI). Although a significant association between focus score (FS) and other disease activity parameters have been found in other pSS cohorts previously, only trends could be noted in our patient group. One explanation for this could be that FS were generally low in our patient groups (Table 1) . Even though, a general pattern of increased levels of T FH -like cells was observed in ANA/SSA+ patients compared to ANA/SSAÀ patients (only significant for ICOS + PD-1 + cells; Figure 9 ). This association could not be made when grouped according to RF and ESSPRI. We found a trend of reduced CD38 À memory B cells levels in patients with indications of increased disease activity (ie ANA/SSA+, RF > 11 and ESSPRI > 5), (Figure 9 ), although only significant for the ANA/SSA subdivision. On the other hand, the CD38 + MCs were more stable according to disease activity parameters. In contrast, the plasma cells and blast levels were higher in the groups with higher disease activity score. We may not have got strong statistical evidence, but taken together, our observations indicate a trend that the disease activity also skews the general PBMC population subsets, to higher T FH , lower memory B cells, and more activated B cells. 
| CONCLUSION
